These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1926916)

  • 1. Rho Chi Lecture. Ideals and innovation: drugs, generics, the FDA, and the pharmacist.
    Benet LZ
    DICP; 1991 Apr; 25(4):427-30. PubMed ID: 1926916
    [No Abstract]   [Full Text] [Related]  

  • 2. Upjohn pharmacist reimbursement programs halted by FDA.
    Am J Hosp Pharm; 1993 Feb; 50(2):200, 205. PubMed ID: 8480773
    [No Abstract]   [Full Text] [Related]  

  • 3. Another round over generics.
    Kosterlitz J
    Natl J (Wash); 1985 Oct; 17(42):2373, 2376. PubMed ID: 10274030
    [No Abstract]   [Full Text] [Related]  

  • 4. Implications of the Lannett and Pharmadyne decisions.
    Vetrano AJ
    Am J Hosp Pharm; 1980 Apr; 37(4):537-40. PubMed ID: 7377217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.
    Euen BJ; Fadda HM
    Res Social Adm Pharm; 2019 Jan; 15(1):77-83. PubMed ID: 29567088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The generic drug scandal and its implications for pharmacy professionals.
    Barone JA; Colaizzi JL; Zorn BK
    DICP; 1990 Jan; 24(1):98-9. PubMed ID: 2301195
    [No Abstract]   [Full Text] [Related]  

  • 7. Generics still a favorite Rx for savings.
    Wagner M
    Mod Healthc; 1990 May; 20(21):26-8, 30, 32-3. PubMed ID: 10104890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of generics will mean cost savings.
    Nelson G
    Internist; 1979 May; 20(4):6-8. PubMed ID: 10242132
    [No Abstract]   [Full Text] [Related]  

  • 9. Generics, Roche joust for Valium market.
    Sun M
    Science; 1985 Apr; 228(4698):472-3. PubMed ID: 3983636
    [No Abstract]   [Full Text] [Related]  

  • 10. Secretary upholds FDA on generics.
    Richards NM
    Pa Med; 1990 Jun; 93(6):28. PubMed ID: 2367133
    [No Abstract]   [Full Text] [Related]  

  • 11. Survey of pharmacists: impact of the generic drug scandal and implications for marketing generic drugs.
    Gupta PB
    Health Mark Q; 1996; 13(3):109-20. PubMed ID: 10158484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA takes action against firms in scandal over generic products.
    Pollner F
    Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA action spurs change in groups' drug programs.
    Perry PA
    Hosp Mater Manage; 1989 Nov; 14(11):1, 13-4. PubMed ID: 10295911
    [No Abstract]   [Full Text] [Related]  

  • 14. Implementing the additional strength biowaiver for generics: EMA recommended approaches and challenges for a US-FDA submission.
    Cardot JM; Garcia-Arieta A; Paixao P; Tasevska I; Davit B
    Eur J Pharm Sci; 2018 Jan; 111():399-408. PubMed ID: 29032306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 16. What's in a name? Generic vs brand name drugs.
    Levin AA
    Health PAC Bull; 1986 Jun; 16(5):37, 39. PubMed ID: 10276741
    [No Abstract]   [Full Text] [Related]  

  • 17. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives. FDA scandal: white hats, black hats, gray areas.
    Wiener JO
    Faulkner Grays Med Health; 1989 Dec; 43(48):suppl 6 p.. PubMed ID: 10296081
    [No Abstract]   [Full Text] [Related]  

  • 19. Obtaining drugs from foreign markets.
    Shirk MB; Hale KN
    Am J Hosp Pharm; 1992 Nov; 49(11):2731-9. PubMed ID: 1471638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: The FDA and the pharmacist as an advisor on nonprescription drugs.
    Zellmer WA
    Am J Hosp Pharm; 1974 May; 31(5):447. PubMed ID: 4829385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.